Demographic trends and KRAS/BRAF^V600E mutations in colorectal cancer patients of South China: A single‐site report

Abstract

The incidence of colorectal cancer (CRC) is increasing in China. Here, we aimed to evaluate the latest demographic trends and KRAS/BRAF mutations status of Chinese CRC. Five thousand five hundred and forty-six CRC patients diagnosed from 2010 to 2017 were involved. KRAS exon 2 and BRAF V600E mutations were detected by Sanger sequencing and high-resolution melting analysis or allelic-specific probe method. Gene mutation profiles and clinicopathologic characteristics of 5495 patients were analyzed. The joinpoint regression model was used to predict the demographic data in 2018. We found KRAS exon 2 and BRAF V600E mutation rates were 37.7 and 2.8% in CRC patients. Tumors with KRAS exon 2 mutations were more likely to be present in female and patients aged older than 75 years, right colon and have well-differentiated histology. Tumors with BRAF V600E mutations were more likely to be present in the female, right colon and have poorly differentiated histology. From 2010 to 2017, the percentage of colon cancer and tubular adenocarcinoma in CRC increased substantially (from 39.3 to 51.8%, from 78.6 to 93.4%, respectively). The percentage of right colon cancer increased from 18.3 to 20.5%, which predictively may keep at 22.6% in 2018. The rise trends for patients with moderate differentiation tumor or KRAS exon 2 mutated tumor were apparent (from 50.3 to 78.6%, from 32.8 to 39.7%, respectively). In conclusion, in recent 8 years, there is a shift to the colon, especially right colon in the incidence of Chinese CRC. Moreover tubular adenocarcinoma is becoming the primary histology type.most common cancer and the fifth leading cause of cancer death. 2,3 In Guangzhou, a more developed coast area in South China, CRC incidence has reached 34/100,000, according to

Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases

“…For the RCC and LCRC clinicopathological characteristics, our findings were similar to those in published data. RCC was more frequently associated with female patients, metastasis, mucinous, poorly-differentiated carcinoma, and a higher correspondence with the BRAF mutation and MSI-H status (Wangefjord et al, 2013;Li et al, 2015;Fu et al, 2019). Furthermore, our results showed that RCC was more common in younger patients who were under 50 years old, providing a diagnostic reference for clinicians.…”

<p>Nomograms for Prediction of Molecular Phenotypes in Colorectal Cancer</p>

“…36 However, several studies showed that BRAF mutation was only found in 2.8-4.4% CRCs in Chinese population. 22,34 In our study, BRAF mutation presented in 3.4% (10/293) cases, which is accordant to the reported mutation rate in Chinese population. These results showed that there may exist a distinct nature of CRC between populations.…”

“…The missense mutations in KRAS occur in approximately 37.5-38% CRCs in Chinese populations. 22,34 A similar sequencing result was found in our cohort, in which KRAS mutation presented in 34.8% (96/276) patients with CRC. KRAS mutation has been found to be more likely to present in female, older patients, and tumors with right-side location, poor differentiation, elevated CEA or CA19-9, and high albumin/globular protein.…”

“…These mutation analyses were performed at the Molecular Laboratory of our institute under a high-quality control as previously described. 22…”

KRAS gene mutation in patients with primary colorectal cancer

“…ın our study population, the overall mutational rate for KRAS was 58.2%, which seemed to be higher to those reported for other populations. Fu X et al [6], found KRAS exon 2 mutation rates were 37.7% in 5546 CRC patients diagnosed from 2010 to 2017. guo F et al [7], KRAS exon 2 mutations were identified in 42.2% in 353 CRC patients from two Chinese clinical centers. Hamzehzadeh l et [8], detected mutations in exon 2 (codons 12 and 13) of the KRAS and NRAS genes using high resolution melting analysis, ıntplex design and Sanger sequencing in 87 ıranian CRC patients.…”